Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4186907 | 0.91 | CA12 (0.50) | APEX1MAPTSMN1; SMN2MEN1LMNA | |
| SCHEMBL13653115 | 0.89 | APEX1 (0.41) | APEX1MAPTSMN1; SMN2MEN1LMNA | |
| SCHEMBL4174953 | 0.87 | CA12 (0.50) | APEX1MAPTTP53CA12CA9 | |
| SCHEMBL4195612 | 0.86 | CA12 (0.45) | APEX1MAPTSMN1; SMN2MEN1LMNA | |
| SCHEMBL4187089 | 0.84 | CA12 (0.49) | LMNACA12CA9ALDH1A1KDM4E | |
| SCHEMBL4195619 | 0.83 | CA12 (0.44) | APEX1SMN1; SMN2MEN1LMNATSHR | |
| SCHEMBL4185822 | 0.83 | HDAC1 (0.50) | MAPTCA12CA9 | |
| SCHEMBL4189530 | 0.82 | KMT2A (0.41) | APEX1MAPTMEN1LMNAKMT2A | |
| SCHEMBL4197907 | 0.82 | HDAC1 (0.45) | MAPTSMN1; SMN2MEN1KMT2ACA12 | |
| SCHEMBL4185649 | 0.81 | CA12 (0.43) | MAPTSMN1; SMN2MEN1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247590-A1 | Indane amides | BAYER PHARMACEUTICLAS CORPORATION (US) | 2009-10-01 | — | — | US | disclosed |
| EP-1802577-A1 | INDANE AMIDES WITH ANTIPROLIFERATIVE ACTIVITY | Bayer Pharmaceuticals Corporation (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006062580-A1 | INDANE AMIDES WITH ANTIPROLIFERATIVE ACTIVITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247590-A1 | Indane amides | MKI67, PPIP5K2, CCNA1 | APEX1 732/4885MAPT 1308/4885SMN1; SMN2 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.